Wa'el Hashad Wa'el Hashad, CEO, Longeveron Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ in rare pediatric disease ...

CT1812 slowed cognitive decline by 95% in Alzheimer’s disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from ...

Third Quarter, Recent Business Highlights and Upcoming Milestones Neurodegenerative Diseases Portfolio Alzheimer's Disease PRX012 ... approximately 260 patients in the ASCENT clinical trials Poster ...

confirming enrollment of individuals with mild-to-moderate DLB This poster is available on the Company's website Continued enrollment in Phase 2 START study (NCT05531656) in early Alzheimer's disease ...

Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ETCompany ParticipantsMarissa Bych - Gilmartin GroupMaria Sainz ...

Enrolled 4 patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with patient dosing advancing as planned; 12-month Cohort 1 and interim Cohort ...

"Up until now, risk models in genomics have relied on broad categories that overlook the specific and unique genetic makeup of each individual," said Giordano Bottà, CEO of Allelica. "This innovation ...

I'm A Celebrity is officially back for its 2024 series - with all the cast beginning to arrive in Australia ahead of Sunday's ...

M Therapeutics Inc. (4MTx), an early-stage biotechnology company developing treatments for neuropsychiatric and neurodegenerative diseases, today announced that the Company has been awarded a $120,000 ...

Research projects by Cameron University chemistry students were among the 250 undergraduate oral and poster presentations featured at the recent American Chemical Society Southwest Regional Meeting in ...

A new Louisiana law that requires the Ten Commandments to be displayed in every public classroom by Jan. 1 has been temporarily blocked after a federal judge granted a preliminary ...